Sunday, June 24, 2012
New Oral MS drug Reduces Brain Lesions
From the 2012 AAN annual meeting, ONO-4641, a potent selective sphingosine-1-phosphate (S1P) receptor agonist (two other similar drugs are Fingolimod...already FDA approved... and BAF), was found to reduce the number of lesions on MRI in patients with the relapsing remitting form of MS.The drug was well tolerated with no unexpected adverse events. Those adverse events were dose related cardiovascular ones. The phase 2b study of ONO-4641 shows that lower doses will be safer.